Ratio may help identify aggressive prostate cancers
Minneapolis-For decades, the Gleason grading system has been the de facto standard used to characterize prostatic tumors. Now, with the help of Donald F. Gleason, MD, himself, researchers from the University of Minnesota have found a way to make the system even more useful to clinicians.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
FDA grants cretostimogene grenadenorepvec Breakthrough and Fast Track Designations for NMIBC
December 5th 2023The designations, which will expedite the development and regulatory review of cretostimogene grenadenorepvec in this setting, are supported by results from the phase 3 BOND-003 trial.
